Samsung Biologics Offers to Buy PolyPeptide for Around $1.8 Billion
By Kwanwoo Jun
Samsung Biologics has offered to buy Swiss contract drug manufacturer PolyPeptide Group for around $1.8 billion.
The South Korean biotechnology company said Monday it has launched an all-cash public tender offer valuing PolyPeptide at 1.46 billion Swiss francs, equivalent to $1.81 billion. The transaction is valued at 2.706 trillion won, Samsung Biologics said.
Under the terms of the offer, PolyPeptide shareholders will receive 44.31 Swiss francs a share, according to both companies.
PolyPeptide's board of directors has unanimously recommended that shareholders accept the offer.
Samsung Biologics expects the transaction to close by the end of 2026, subject to regulatory approvals.
PolyPeptide is a Swiss contract development and manufacturing organization that develops and manufactures peptide ingredients for pharmaceutical and biotechnology companies.
The deal would help Samsung Biologics strengthen its presence in the rapidly growing market for peptide-based therapeutics, including treatments for obesity and diabetes.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
July 19, 2026 21:41 ET (01:41 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States